Study incorporates genetics with smoking history to identify high-risk smokers for lung cancer screening

A study by Vanderbilt researchers that analyzed both smoking history and genetic risk variants for lung cancer supports modifying current guidelines to include additional smokers for lung cancer screening.

Arthritis drug may treat immunotherapy-related heart complication

New drug for metastatic colorectal cancer enters phase 3 trial

A new therapy for metastatic colorectal cancer that has been granted fast track designation by the U.S. Food and Drug Administration is being tested in a phase 3 clinical trial at Vanderbilt-Ingram Cancer Center.

Study underscores importance of personalized medicine in kidney cancer

A new study sheds light on how molecular subsets within the tumors of kidney cancer patients determine treatment outcomes and underscores the importance of personalized medicine in making therapy decisions.

Erlanger Health System and Vanderbilt-Ingram Cancer Center partner in cancer care

Erlanger Health System and Vanderbilt University Medical Center, on behalf of Vanderbilt-Ingram Cancer Center (VICC), have entered into a professional service agreement designing a long-term collaboration in comprehensive cancer care, including VICC hematology-oncology services at Erlanger Oncology and Hematology and infusion locations.

VICC receives ‘exceptional’ score with renewal as an NCI-Designated Comprehensive Cancer Center

Vanderbilt-Ingram Cancer Center (VICC) received an overall “exceptional” score for its research impact and excellence in patient care. This achievement merits renewed funding from the National Cancer Institute (NCI) and places it once again in a top group of NCI Comprehensive Cancer Centers.